Get the Stockscreener App
28.52
2.37%
0.66
After Hours:
28.52
Castle Biosciences Inc stock is traded at $28.52, with a volume of 338.10K.
It is up +2.37% in the last 24 hours and down -3.88% over the past month.
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
See More
Previous Close:
$27.86
Open:
$27.86
24h Volume:
338.10K
Relative Volume:
0.83
Market Cap:
$778.71M
Revenue:
$219.79M
Net Income/Loss:
$-57.47M
P/E Ratio:
-8.5134
EPS:
-3.35
Net Cash Flow:
$-19.25M
1W Performance:
-4.84%
1M Performance:
-3.88%
6M Performance:
+28.76%
1Y Performance:
+68.86%
1-Day Range:
$27.81
$28.96
1-Week Range:
$27.81
$30.11
52-Week Range:
$12.07
$32.53
Castle Biosciences Inc Stock (CSTL) Company Profile
Name
Castle Biosciences Inc
Sector
Industry
Phone
866-788-9007
Address
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Apr-30-21 | Initiated | Lake Street | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-27-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | BTIG Research | Buy |
| Aug-19-19 | Initiated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | Robert W. Baird | Outperform |
| Aug-19-19 | Initiated | SVB Leerink | Outperform |
View All
Castle Biosciences Inc Stock (CSTL) Latest News
New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carci - StockTitan
Renaissance Technologies LLC Acquires 96,800 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Castle Biosciences, Inc. (NASDAQ:CSTL) Holdings Lowered by Yu Fan - MarketBeat
New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences’ TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barrett’s Esophagus - StockTitan
Inspire Investing LLC Makes New Investment in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Castle Biosciences (NASDAQ:CSTL) Trading 4% Higher - MarketBeat
Castle Biosciences (NASDAQ:CSTL) Shares Down 2.1% - MarketBeat
Castle Biosciences CEO sells over $158k in company stock By Investing.com - Investing.com Australia
Castle Biosciences CEO sells over $158k in company stock By Investing.com - Investing.com Canada
Castle Biosciences CEO sells over $158k in company stock - Investing.com India
Castle Biosciences CEO sells over $158k in company stock By Investing.com - Investing.com UK
Castle Biosciences (NASDAQ:CSTL) Sets New 52-Week High at $31.91 - MarketBeat
Castle Biosciences’ COO Kristen Oelschlager Honoured as Arizona Bioscience Leader of the Year. - TechBullion
Castle Biosciences (NASDAQ:CSTL) shareholder returns have been favorable, earning 87% in 1 year - Simply Wall St
Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year - StockTitan
Eye Cancer Diagnosed at 13 , Presley's story of Inspiration Ocular Melanoma - Audacy
Acadian Asset Management LLC Acquires 69,673 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Castle Biosciences (NASDAQ:CSTL) Hits New 52-Week High at $30.66 - MarketBeat
Castle Biosciences stock soars to 52-week high of $30.59 - Investing.com
Castle Biosciences stock soars to 52-week high of $30.59 - Investing.com India
Castle Biosciences stock soars to 52-week high of $30.59 By Investing.com - Investing.com UK
CSTL (Castle Biosciences Inc) may reap gains as insiders became active recently - Knox Daily
DecisionDx®-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms - Business Wire
Castle Biosciences director sells over $228k in company stock By Investing.com - Investing.com Australia
Castle Biosciences director sells over $228k in company stock - Investing.com
Castle Biosciences director sells over $228k in company stock By Investing.com - Investing.com Canada
Insider Sale: COO Kristen Oelschlager Sells Shares of Castle Biosciences Inc (CSTL) - Yahoo Finance
Insider Sale: COO Kristen Oelschlager Sells Shares of Castle Biosciences Inc (CSTL) By GuruFocus - Investing.com Canada
Insider Sale: COO Kristen Oelschlager Sells Shares of Castle Bio - GuruFocus.com
Pres. & Chief Exec. Officer MAETZOLD DEREK J sale 2,246 shares of Castle Biosciences Inc [CSTL] - Knox Daily
Study Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma - Business Wire
Study Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma - The Bakersfield Californian
Castle Biosciences CEO sells over $133k in company stock By Investing.com - Investing.com Australia
Castle Biosciences CEO sells over $133k in company stock - Investing.com
Castle Biosciences CEO sells over $133k in company stock - Investing.com India
Castle Biosciences CEO sells over $133k in company stock By Investing.com - Investing.com UK
Castle Biosciences Inc (CSTL) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Guggenheim analysts initates a Buy rating for Castle Biosciences Inc (CSTL) - Knox Daily
Lisanti Capital Growth LLC Takes $2.10 Million Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
Castle Biosciences levels up with Partners’ Friendswood HQ development - The Real Deal
Castle Biosciences (NASDAQ:CSTL) Hits New 12-Month High at $30.50 - MarketBeat
Cancer diagnostics co. Castle Biosciences to build new headquarters in Friendswood - The Business Journals
CSTLCastle Biosciences, Inc. Latest Stock News & Market Updates - StockTitan
Castle Biosciences to Participate in Upcoming Investor Conferences - Business Wire
Legato Capital Management LLC Purchases Shares of 14,155 Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat
The Attractiveness of Investing In Castle Biosciences Inc (CSTL) is Growing - Knox Daily
Castle Biosciences (NASDAQ:CSTL) Sees Unusually-High Trading Volume - MarketBeat
Castle Biosciences (NASDAQ:CSTL) Trading Down 4.2% - MarketBeat
23,812 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Acquired by Summit Global Investments - MarketBeat
Castle Biosciences stock soars to 52-week high of $28.26 By Investing.com - Investing.com Australia
Stock Performance Spotlight: Castle Biosciences Inc (CSTL) Ends the Day at 27.96, Up by 3.59 - The Dwinnex
Castle Biosciences Inc Stock (CSTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
1.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):